| abstract |
A controlled release pharmaceutical composition comprising a biocompatible polymeric material, preferably a copolymer of ethylene and vinyl acetate or a copolymer of lactic and glycolic acids, containing a soluble receptor introduced into it that can bind to the ligand and thus affect the function of the ligand. The soluble receptor is preferably a soluble form of the TNFa receptor. Such compositions are intended for use in the treatment of diseases in which the neutralization of the harmful effects of TNFa is necessary. The international application was published along with an international search report. |